Stem-cell treatment company Pluristem Therapeutics, Inc. (NASDAQ:PSTI) shares take off subsequent to word that a third critically ill patient received treatment with its med and that the “outcome of those treatments potentially suggests that the company’s PLX cells may have significant potential to treat a range of indications of bone marrow diseases.”
Novartis AG’s (NYSE:NVS) Gilenya treatment for multiple sclerosis, and AstraZeneca’ Group plc’s (NYSE:AZN) Caprelsa for thyroid cancer, along with Boehringer Ingelheim’s Pradaxa drug for stroke prevention are all said to have ‘problems’, in an American Medical Association article by Thomas Moore and Curt Furberg. The authors believe that the FDA expedite the approvals for the drugs, and in doing so might have undermined safety.
Amarin Corporation PLC (NASDAQ:AMRN) reports that the United States Patent and Trademark Office gave a Notice of Allowance for two additional Marine Patent Applications which would cover its Vascepa into 2030. This new notice follows Tuesday’s announcement that it had received a like notification for its Vascepa patent titled “Method of Treating Hypertriglyceridemia.” MKM Partners sees the significance of these patents, remarking that they are “clearly important for AMRN to secure a partnership or acquisition.”
Don’t Miss: This FDA Scandal May Harm Drug Stocks.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>